INKT Quote, Financials, Valuation and Earnings

Capricor Therapeutics has a net margin of -- compared to MiNK Therapeutics's net margin of -63.94%. MiNK Therapeutics's return on equity of -- beat Capricor Therapeutics's return on equity of -75.99%.

MiNK Therapeutics has a consensus price target of $39.00, signalling upside risk potential of 92.02%. On the other hand Capricor Therapeutics has an analysts' consensus of $20.60 which suggests that it could grow by 199.42%. Given that Capricor Therapeutics has higher upside potential than MiNK Therapeutics, analysts believe Capricor Therapeutics is more attractive than MiNK Therapeutics.

MiNK Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Capricor Therapeutics has a beta of 0.820, suggesting its less volatile than the S&P 500 by 18.02%.

MiNK Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MiNK Therapeutics pays -- of its earnings as a dividend. Capricor Therapeutics pays out -- of its earnings as a dividend.

MiNK Therapeutics quarterly revenues are --, which are smaller than Capricor Therapeutics quarterly revenues of $11.1M. MiNK Therapeutics's net income of -$2.8M is higher than Capricor Therapeutics's net income of -$24.4M. Notably, MiNK Therapeutics's price-to-earnings ratio is -- while Capricor Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiNK Therapeutics is -- versus 12.00x for Capricor Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to MiNK Therapeutics's net margin of --. MiNK Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

MiNK Therapeutics has a consensus price target of $39.00, signalling upside risk potential of 92.02%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 5961.21%. Given that CEL-SCI has higher upside potential than MiNK Therapeutics, analysts believe CEL-SCI is more attractive than MiNK Therapeutics.

MiNK Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

MiNK Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MiNK Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

MiNK Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. MiNK Therapeutics's net income of -$2.8M is higher than CEL-SCI's net income of -$6.6M. Notably, MiNK Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiNK Therapeutics is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to MiNK Therapeutics's net margin of 21.63%. MiNK Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

MiNK Therapeutics has a consensus price target of $39.00, signalling upside risk potential of 92.02%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 19.45%. Given that MiNK Therapeutics has higher upside potential than Pfizer, analysts believe MiNK Therapeutics is more attractive than Pfizer.

MiNK Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

MiNK Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.95% to investors and pays a quarterly dividend of $0.43 per share. MiNK Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

MiNK Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. MiNK Therapeutics's net income of -$2.8M is lower than Pfizer's net income of $3B. Notably, MiNK Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiNK Therapeutics is -- versus 2.23x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Walgreens Boots Alliance has a net margin of -- compared to MiNK Therapeutics's net margin of -0.45%. MiNK Therapeutics's return on equity of -- beat Walgreens Boots Alliance's return on equity of -58.91%.

MiNK Therapeutics has a consensus price target of $39.00, signalling upside risk potential of 92.02%. On the other hand Walgreens Boots Alliance has an analysts' consensus of $11.93 which suggests that it could grow by 3.81%. Given that MiNK Therapeutics has higher upside potential than Walgreens Boots Alliance, analysts believe MiNK Therapeutics is more attractive than Walgreens Boots Alliance.

MiNK Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Walgreens Boots Alliance has a beta of 0.778, suggesting its less volatile than the S&P 500 by 22.237%.

MiNK Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Walgreens Boots Alliance offers a yield of 8.7% to investors and pays a quarterly dividend of $0.25 per share. MiNK Therapeutics pays -- of its earnings as a dividend. Walgreens Boots Alliance pays out -14.59% of its earnings as a dividend.

MiNK Therapeutics quarterly revenues are --, which are smaller than Walgreens Boots Alliance quarterly revenues of $39B. MiNK Therapeutics's net income of -$2.8M is higher than Walgreens Boots Alliance's net income of -$175M. Notably, MiNK Therapeutics's price-to-earnings ratio is -- while Walgreens Boots Alliance's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiNK Therapeutics is -- versus 0.06x for Walgreens Boots Alliance. Usually stocks with elevated PS ratios are considered overvalued.